Gut microbiota and autoimmune diseases: Insights from Mendelian randomization

Fangxiang Mu,Gusbakti Rusip,Florenly Florenly
DOI: https://doi.org/10.1096/fba.2024-00037
2024-09-23
FASEB BioAdvances
Abstract:Gut microbiota is significantly linked to autoimmune diseases (AID) like systemic lupus erythematosus (SLE), multiple sclerosis (MS), and rheumatoid arthritis (RA). These associations include changes in gut microbial diversity and the abundance of specific gut microbiota, but they do not necessarily imply causation. Given the innovative potential of Mendelian randomization in uncovering the etiology of AID, this review outlines the methodology and its recent applications in studying SLE, MS, and RA. In recent years, the scientific community has shown interest in the role of gut microbiota in the development of autoimmune diseases (AID). Although observational studies have revealed significant associations between gut microbiota and AID like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, these connections do not necessarily imply causality. Mendelian randomization (MR) approach has been extensively employed to investigate the causal relationship. Relevant MR study findings indicate that a reduction in beneficial microbial populations, particularly Bifidobacterium and Lactobacillus, and an increase in potential pathogenic microbes, is correlated with an elevated AID risk. Given the innovative potential of MR in unraveling the etiopathogenesis of AIDs, this article offers an overview of this methodological approach and its recent applications in AID research.
What problem does this paper attempt to address?